GlassScriptPhysician profile
Douglas K Blacklidge
NPI 1003901133
$688,538.44
in general payments reported to CMS, 2019-2025
35 companies · $44K in 2025
The $44K reported for 2025 was more than what 99% of Foot & Ankle Surgery providers received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $120K · 2020: $103K · 2021: $122K · 2022: $135K · 2023: $81K · 2024: $85K · 2025: $44K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $176K · Consulting Fee: $26K · Travel and Lodging: $3,770 · Food and Beverage: $2,332.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $176,440.26 |
| Consulting Fee | $26,362.50 |
| Travel and Lodging | $3,769.64 |
| Food and Beverage | $2,332.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paragon 28, INC. | $492,075.74 | 2019-2025 | Portfolio, Apex 3d, Gorilla |
| Stryker Corporation | $143,980.04 | 2020-2025 | Claw II, Ortholoc 3di, Inbone |
| Wright Medical Technology, INC. | $30,159.10 | 2019-2020 | |
| Extremity Medical | $17,204.02 | 2022-2025 | Lapidus, Lapidus Instruments |
| Novastep INC. | $1,523.10 | 2020-2022 | |
| Crossroads Orthopedics, LLC | $1,314.41 | 2020-2021 | |
| Treace Medical Concepts, INC. | $1,245.66 | 2024-2025 | |
| Flower Orthopedics Coporation | $149.45 | 2022 | |
| Depuy Synthes Sales INC. | $124.07 | 2019-2025 | Motoband, Foot Osteotomy Wedge System |
| Triad Life Sciences INC. | $80.43 | 2022 | |
| Fusion Orthopedics USA, LLC | $60.57 | 2025 | |
| Cardiovascular Systems INC. | $51.98 | 2019 | |
| Terumo Bct, INC. | $49.45 | 2020 | |
| Integra Lifesciences Corporation | $47.61 | 2019-2020 | |
| Trilliant Surgical LLC. | $43.20 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $39.39 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Abbott Laboratories | $33.09 | 2025 | Proclaim |
| Medshape, INC. | $29.67 | 2022 | |
| Horizon Therapeutics Plc | $29.03 | 2019 | |
| Summ Cott Medical | $29.00 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $27.68 | 2023 | Seglentis |
| Djo, LLC | $26.16 | 2019-2023 | Donjoy |
| Averitas Pharma INC. | $22.52 | 2025 | Qutenza |
| Medtronic, INC. | $21.36 | 2024 | Kyphon Express II Kyphopak Tray |
| Dynasplint Systems INC. | $20.30 | 2019 | |
| Boston Scientific Corporation | $19.31 | 2024 | |
| Zimmer Biomet Holdings, INC. | $19.00 | 2021 | |
| Dexcom, INC. | $18.38 | 2025 | Dexcom G6 Transmitter |
| Orthofix Medical, INC. | $17.98 | 2025 | Physio-Stim |
| Kci USA, INC. | $14.35 | 2020 | |
| Mimedx Group, INC. | $14.30 | 2024 | |
| Smith+Nephew, INC. | $13.38 | 2021 | |
| Merck Sharp & Dohme LLC | $13.05 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $11.05 | 2019 | |
| Checkpoint Surgical, INC | $10.61 | 2023 | Checkpoint Stimulators |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,332,892.88 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Blacklidge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.